Akums Drugs and Pharmaceuticals Limited
Established in 2004, Akums Drugs and Pharmaceuticals Limited is a pharmaceutical contract development and manufacturing organization (CDMO) offering a comprehensive range of pharmaceutical products and services.
What Akums files
- Others54
- Investor Meet45
- Important34
- Updates15
- Board Meeting12
- PPTs6
Akums Drugs received an ESG rating of '65' from NSE Sustainability. This rating was voluntarily assigned based on publicly available information, highlighting the company's environmental, social, and governance performance.
Akums reported strong Q1 FY27 results. Revenue surged 13.9% YoY to ₹1,167 Cr, EBITDA grew 35.4% to ₹175 Cr, and PAT hit ₹101 Cr. CDMO business was the key driver, fueled by volume growth.
Akums Drugs' subsidiary will acquire Oriflame India's manufacturing business for 56 Cr cash. This includes two plants and a warehouse, marking Akums' entry into color cosmetics and expanding its skincare & wellness portfolio. Strategic move to boost manufacturing capabilities.
Akums Drugs and Pharmaceuticals has announced its 22nd AGM on July 10. The Board proposes a final dividend of Re 1 and a special dividend of Rs 2 per equity share, totaling Rs 3. The record date for this 150% dividend is July 3.
Akums posted robust Q4 & FY26 results: Revenue up 9.7% to ₹1,158 Cr (Q4) & 5.9% to ₹4,359 Cr (FY26), with Adj PAT surging 135% (Q4) & 27.3% (FY26). CDMO business drove growth. Global expansion continued; API segment faces pricing pressure. Board declared a ₹3/share dividend.